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The standard deviation of units-per-day over the year was used
as the proxy measure of non-adherence. Total and diabetes-
attributable costs were computed including insurance payments
and patients’ co-payments. Multivariate log-linear regressions
were estimated for costs using variability in long/intermediate-
acting insulin, diabetes severity, overall comorbidity burden, hos-
pitalization in prior six-months, insulin pump use, concomitant
use of short-acting insulin, oral antidiabetic medications, patient
initiating antidiabetic therapy, insurance plan, and demographic
variables. RESULTS: A total of 11,125 patients had at least three
prescriptions for long-acting or intermediate-acting insulin and
were used in the models. The standard deviation of units-per-day
ranged from zero to 210, with a median of 11 and 20th and 80th
percentiles of ﬁve and 23, respectively. Total costs increased
0.39% and diabetes-attributable costs increased 0.31% for each
unit increase in the standard deviation of insulin units-per-day.
CONCLUSIONS: Increased variability of insulin use increases
total and diabetes-attributable annual costs.
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DEVELOPMENT OF AN INTEGRATED DIABETES DATABASE
ACROSS COMMUNITY CLINICS AND HOSPITALS
Ho MJ1, Sauer B2, Stockdale B1, Brixner D1
1University of Utah, Salt Lake City, UT, USA; 2Veterans Affairs,
Salt Lake City, Salt Lake City, UT, USA
Electronic medical records (EMR) have been incorporated into
many health care settings to assist physicians in sharing patient
information effectively across health care providers. Most EMRs
were designed to optimize sharing of clinical information and
not to accommodate the needs of health services researchers.
Building a comprehensive database that includes information
from multiple databases and EMR sources can be challenging.
OBJECTIVE: To develop a comprehensive diabetes dataset of
clinical resource utilization information and costs using a com-
munity clinics and hospital based EMR and charge data. This
allows a direct comparison of resource utilization and econom-
ics associated with various anti-diabetic treatments. METHODS:
Prescription order data for patients on anti-diabetic medications
or with a diagnosis of diabetes in 2001–2003 were obtained from
the community clinics EMR system. Other health care informa-
tion was collected from the hospital outpatient clinics and hos-
pital EMR systems. Pertinent health care information included
site of care, procedures performed, laboratory tests results, and
diagnosis. Missing information was retrieved manually from the
EMR chart from physician notes which are not transferred to
the EMR database or imputed from retrieved data sources.
Resource use information was matched to ﬁnancial data based
on patient visit numbers. Professional charges were matched to
each visit based on patient identiﬁer and approximate visitation
date, with Institutional Review Board approval. RESULTS: The
ﬁnal dataset includes pertinent clinical, costs resource utilization
information for patients suffering from diabetes across 810
patients receiving insulin. This dataset was used to determine the
differences in resources and cost differences between different
insulin regimens. CONCLUSION: Integrated data systems
across outpatient and inpatient settings can be very useful in out-
comes research however pulling together information from
various datasets can be challenging.
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THE USE OF DIABETES PREVENTION PROGRAM RESULTS TO
MODEL COST-EFFECTIVENESS OF THE INTERVENTION IN A
MORE GENERALIZED HYPOTHETICAL POPULATION
Novak S, Lawson K,Wilson J
University of Texas at Austin, Austin,TX, USA
OBJECTIVES: The Diabetes Prevention Program (DPP)
excluded subjects at baseline due to multiple disease states. The
objectives of this study were to 1) design a long-term cost-
effectiveness model to evaluate the use of intensive lifestyle inter-
vention to prevent type-2 diabetes (T2DM) based on the DPP
study design; and 2) attempt to project these ﬁndings onto a
more generalized hypothetical population than that studied by
the DPP. METHODS: Markov models were developed based on
the DPP results incorporating the states of normal glucose tol-
erance, impaired glucose tolerance, T2DM and death. Transition
probabilities were derived from DPP and current literature. 
A three-year intervention was assumed with outcomes of 1) a 
three-year duration of effect; and 2) a lifetime duration of effect.
A second set of models, based on a hypothetical, more general-
ized population included higher direct medical control cost of
illness, and US Life Table mortality ﬁgures. RESULTS: Lifestyle
dominated placebo in both models, with the following results
derived for incremental cost-effectiveness ratios: 1) DPP model—
3-year duration = -$6,319/LY; 2) DPP model—lifetime duration
= -$11,804/LY; 3) generalized model—three-year duration =
-$16,064/LY; and 4) generalized model—lifetime duration =
-$19,496/LY. A maximal acceptable cost of intervention per year
for the three-year duration of effect that could be used to main-
tain lifestyle domination was also established. These values were:
1) DPP model—three-year duration = $1820/year; 2) DPP
model—lifetime duration = $6500/year; 3) generalized model—
three-year duration = $2910, and 4) generalized model—lifetime
duration = $9750. CONCLUSION: In this model that examined
an intervention that had little apparent effect on life expectancy,
increasing control cost of illness increased incremental costs and
incremental cost-effectiveness ratios, and ultimately increased
the apparent cost-effectiveness of this preventive treatment.
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OBJECTIVE: The objective was to validate the construct of the
German-translated version of the Norfolk QOL-DN by factor
analysis in a German population with ﬁve stages of neuropathy
and correlate the resulting factors with degrees of neuropathy.
METHODS: Conducted in 97 sites in Germany, 186 patients
(type-1 n = 33; type-2 n = 153) with diabetic neuropathy were
assessed and categorized: asymptomatic DN (n = 40); sympto-
matic DN (n = 46); DN with history of foot ulcers (n = 32); DN
with amputations (n = 22); and DN with history of amputations
(n = 46). Data was assessed from completion of two self-
administered HQOL questionnaires: Short Form-12 (SF-12) and
Norfolk QOL-DN, a 47 item nerve ﬁber speciﬁc tool, back and
forward translated from English into German. Factor analysis by
Varimax rotation was performed; relationship of the factors to
stages of complications was conducted using two METHODS:
least squares regression and PLUM. Complication stage was
entered as the dependent variable, with all ﬁve factors as pre-
dictors. RESULTS: Five factors resulted from analysis of this
German neuropathy population (multi-staged), matching factors
from a European study population (mild neuropathy). The ﬁrst
factor (Functional Status/Large Fiber) and third factor Activities
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of Daily Living (ADLs) were positively associated with more
advanced stages of neuropathy and accounted for 59.66% of
variance. Factors two (Symptoms), four (Autonomic Neuropa-
thy) and ﬁve (Small Fiber) did not show a signiﬁcant association
with neuropathy stages. Regression with all ﬁve factors had 
R-square of 0.28, replicated across both regression methods.
CONCLUSIONS: The ﬁve resulting factors from the analysis of
the German translated QOL database, matched those from the
factor analysis using the original English version of the Norfolk
QOL-DN in a European study. Two factors, Functional
Status/Large Fiber and (ADLs) were positively associated with
more advanced stages of neuropathy.
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ESTIMATING THE EFFECT OF SYMPTOMS OF DIABETIC
PERIPHERAL NEUROPATHY AND DIABETIC 
RETINOPATHY ON QUALITY-OF-LIFE USING DATA FROM 
THE 2001–2002 NATIONAL HEALTH AND NUTRITION
EXAMINATION SURVEY
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OBJECTIVES: To evaluate the effect of symptoms of diabetic
peripheral neuropathy (SDPN), diabetic retinopathy (DR) and
co-morbid SDPN & DR (COMORB) on the Healthy Days Core
Module (HRQOL-4) measures of the CDC, among US adults
≥40 years old with diagnosed diabetes, using the 2001–2002
National Health and Nutrition Examination Survey (NHANES).
METHODS: Logistic and ordinary least squares (OLS) regres-
sion models were used to assess the impact of SDPN, DR and
COMORB on HRQOL-4 measures. Included in the analysis
were 429 NHANES respondents ≥40 years old classiﬁed as
having diagnosed diabetes. Model covariates included age,
gender, race, education, current smoking status, currently asth-
matic, and history of cardiovascular disease, cancer, arthritis,
COPD, hypertension and stroke. The conditions of interest were
assessed based upon respondent self-report. All estimates were
generated using Stata statistical software, and accounted for 
the complex survey design of NHANES. RESULTS: Using the
2001–2002 NHANES, we estimated that, among US adults ≥40
years old with diagnosed diabetes, those with SDPN (OR = 7.66;
95%CI = 2.90, 20.23), DR (3.43; 1.53, 7.69), and COMORB
(5.43; 2.32, 12.73) were all more likely to report that they were
currently in poor health, compared to those without the condi-
tion of interest. Additionally, OLS models suggest that those 
with SDPN had a signiﬁcantly greater number of days during the
past month in which their physical health was not good, com-
pared to those without SDPN. SDPN was also associated with a
signiﬁcantly greater number of days during the past month in
which poor physical or mental health limited usual activities.
CONCLUSION: Among US adults ≥40 years old with diagnosed
diabetes, SDPN, DR, and COMORB all appear to have a 
signiﬁcant negative effect on quality-of-life. Future therapies 
that offer relief of these conditions may have considerable
humanistic beneﬁts.
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ASSOCIATIONS AMONG VISUAL IMPAIRMENT, STAGE OF
DIABETIC RETINOPATHY AND QUALITY OF LIFE (EQ-5D)
Smith D1, Johnson E1, Russell A1, Hazlehurst B1, Muraki C1,
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OBJECTIVES: The quality-of-life impact of diabetic retinal
disease progression has not been studied using internationally
standardized measures. We undertook an examination of the
relationship between visual impairment, stage of diabetic
retinopathy and quality of life. METHODS: In 2003, we mailed
a questionnaire containing the EuroQol (EQ-5D) quality of life
instrument to a random sample of Kaiser Permanente members
with type-2 diabetes. Of the 2376 patients (59%) who completed
the questionnaire, 155 patients had an eye exam with an ICD-
9-CM diagnosis of nonproliferative or proliferative retinopathy
(NPDR or PDR) during the ﬁrst six-months of 2003. After visual
acuity (VA) data had been removed from the text of the elec-
tronic medical record notes, one of us (CM) staged the retinopa-
thy in these patients by applying the American Academy of
Ophthalmology’s (AAO) International Diabetic Retinopathy
Severity Scale to the notes. A different reviewer abstracted best-
corrected VA in each eye from unmasked notes. Analysis was
based on the better-seeing eye. RESULTS: We obtained complete
data for VA, EQ5D, and AAO staging in 99 eyes with better
acuity. Patients who suffered impaired visual acuity (VA <= 0/40)
reported a generally worse quality of life than patients without
impairment (VA > 20/40). For those with least severe NPDR, the
median EQ5D scores were 0.73 (25th and 75th percentile 0.62,
1.0) among those with no visual impairment, compared with
0.69 (0.69, 0.8) among those with visual impairment. For those
with the PDR, the median EQ5D scores were 0.66 (0.62, 0.80)
among those with no visual impairment, compared with 0.52
(0.13, 0.73) among those with impaired VA. Among patients
with normal visual acuity, we observed a graded negative 
relationship between diabetic retinonopathy progression (AAO
stages) and median EQ-5D scores. CONCLUSION: A generally
decreasing quality of life is observed with more impaired VA and
more severe stages of diabetic retinopathy.
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IS DIABETES KNOWLEDGE ASSOCIATED WITH HEALTH-
RELATED QUALITY OF LIFE AMONG ENGLISH-SPEAKING
SUBJECTS WITH DIABETES IN SINGAPORE?
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OBJECTIVES: To evaluate if diabetes knowledge is associated
with health-related quality of life (HRQoL) among English-
speaking subjects with diabetes in Singapore. METHODS:
English-speaking subjects (aged >21) with self-reported diabetes
mellitus were recruited by convenience sampling at a public event
organized by Diabetic Society of Singapore to commemorate
World Diabetes Day. Correlation between diabetes knowledge
(measured using the General Diabetes Knowledge Test (GDKT),
range 0–100) and HRQoL (measured using the Audit of 
Diabetes-dependent Quality of life (ADDQoL), range 0–100;
EQ-5D, range C0.594 to 1.00 and the SF-6D, range 0.26–1.00)
were studied using Pearson correlation coefﬁcients. The rela-
tionship between diabetes knowledge and HRQoL was studied
using three separate multiple linear regression (MLR) models
with HRQoL scores as the dependent variable and GDKT score
as an independent variable while adjusting for age, gender, eth-
nicity, education, housing type, smoking status and presence of
acute/chronic medical conditions and diabetes complications.
RESULTS: Data from 42 subjects with complete responses were
analyzed (mean (SD) age: 53.0 (9.61) years, 45.0% female,
90.0% with >six years of education, 64.3% with other chronic
medical conditions, 40.5% with diabetes complications). Mean
(SD) GDKT, ADDQoL, EQ-5D and SF-6D scores were 33.1
(3.53), 46.9 (18.56), 0.9 (0.15) and 0.8 (0.14) respectively. 
